Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical TrialsYucai Wang, Michael Wang|JAMA Oncology|2019Cited by 829
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, Nirav N. Shah et al.|The Lancet|2021Cited by 456
Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experienceYasuhiro Oki, Jason R. Westin, Mansoor Noorani et al.|British Journal of Haematology|2014Cited by 364
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan Fowler, Sattva S. Neelapu, R. Eric Davis et al.|The Lancet Oncology|2014Cited by 263
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K. Stein‐Thoeringer, Eran Elinav, Eli Zamir et al.|Nature Medicine|2023Cited by 226